Log in

NASDAQ:NVCR - Novocure Stock Price, Forecast & News

$93.16
+0.24 (+0.26 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$92.24
Now: $93.16
$93.98
50-Day Range
$74.97
MA: $85.84
$95.65
52-Week Range
$41.51
Now: $93.16
$98.84
Volume413,226 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:NVCR
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.07. The medical equipment provider had revenue of $92.06 million for the quarter, compared to analyst estimates of $87.12 million. The firm's quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) earnings per share. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

How can I listen to Novocure's earnings call?

Novocure will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Novocure issued on next quarter's earnings?

Novocure issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 analysts have issued twelve-month price objectives for Novocure's stock. Their forecasts range from $50.00 to $97.00. On average, they expect Novocure's share price to reach $80.33 in the next year. This suggests that the stock has a possible downside of 13.8%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

Media stories about NVCR stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Novocure.

Are investors shorting Novocure?

Novocure saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,110,000 shares, an increase of 5.4% from the January 15th total of 3,900,000 shares. Based on an average daily volume of 906,500 shares, the days-to-cover ratio is currently 4.5 days. Approximately 5.2% of the company's shares are sold short. View Novocure's Current Options Chain.

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.31%), Baillie Gifford & Co. (8.09%), Renaissance Technologies LLC (2.27%), State Street Corp (1.69%), Eagle Asset Management Inc. (0.82%) and Mitsubishi UFJ Trust & Banking Corp (0.63%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which institutional investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Mitsubishi UFJ Trust & Banking Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, UBS Asset Management Americas Inc., Nicholas Investment Partners LP, Jacobs Levy Equity Management Inc. and Citigroup Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which institutional investors are buying Novocure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Invus Financial Advisors LLC, FMR LLC, Fiera Capital Corp, Panagora Asset Management Inc., State Street Corp, Pictet Asset Management Ltd., California Public Employees Retirement System and Bank of Montreal Can. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $93.16.


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  382 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel